FDA Green Lights Bizengri Drug To Treat Rare, Aggressive Bile Duct Cancer HealthDay 16:34 Mon, 11 May
Partner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancer FiercePharma 16:13 Mon, 11 May
Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher PR Newswire (Press Release) 11:01 Mon, 11 May
Partner Therapeutics Announces Receipt of FDA Commissioner's National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma PR Newswire (Press Release) 14:33 Wed, 06 May
